@pedslupusrenal.bsky.social
The FDA approved Yartemlea (narsoplimab-wuug) for transplant-associated thrombotic microangiopathy, or TA-TMA, marking the first approved treatment for the condition. Narsoplimab is a MASP-2 Inhibitor, which targets the Lectin Pathway of complement.
pubmed.ncbi.nlm.nih.gov/41071950/
pubmed.ncbi.nlm.nih.gov/41071950/
Survival in Adults with High Risk TA-TMA - A Comparative Analysis of Narsoplimab Versus Supportive Care - PubMed
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a potentially fatal multisystem complication of hematopoietic cell transplantation (HCT) for which there is no approved treatment. In a single-arm study (NCT02222545), narsoplimab treatment for TA-TMA demonstrated a …
pubmed.ncbi.nlm.nih.gov
December 29, 2025 at 6:25 PM
The FDA approved Yartemlea (narsoplimab-wuug) for transplant-associated thrombotic microangiopathy, or TA-TMA, marking the first approved treatment for the condition. Narsoplimab is a MASP-2 Inhibitor, which targets the Lectin Pathway of complement.
pubmed.ncbi.nlm.nih.gov/41071950/
pubmed.ncbi.nlm.nih.gov/41071950/
www.lupus.org/news/fda-app... and then there were three triple therapies approved for lupus nephritis
FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease...
www.lupus.org
October 21, 2025 at 3:35 AM
www.lupus.org/news/fda-app... and then there were three triple therapies approved for lupus nephritis
Sad state of affairs for research
August 22, 2025 at 7:06 PM
Sad state of affairs for research
www.managedhealthcareexecutive.com/view/fda-app...
C3G and Immune complex glomerulonephritis has a targeted therapy
C3G and Immune complex glomerulonephritis has a targeted therapy
FDA Approves Empaveli for Two Rare Kidney Diseases
C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a high risk of kidney failure. Empaveli is also approved to treat patients with...
www.managedhealthcareexecutive.com
August 2, 2025 at 7:04 PM
www.managedhealthcareexecutive.com/view/fda-app...
C3G and Immune complex glomerulonephritis has a targeted therapy
C3G and Immune complex glomerulonephritis has a targeted therapy
Wear purple 💜 Today is #WorldLupusDay! I’d like to advocate for those affected by #lupus, honor every lupus champion, and celebrate all who are making a difference. We stand together! You are not alone.
#lupusresearch: bit.ly/ManyOneCan2025
#lupusresearch: bit.ly/ManyOneCan2025
May 10, 2025 at 6:57 PM
Wear purple 💜 Today is #WorldLupusDay! I’d like to advocate for those affected by #lupus, honor every lupus champion, and celebrate all who are making a difference. We stand together! You are not alone.
#lupusresearch: bit.ly/ManyOneCan2025
#lupusresearch: bit.ly/ManyOneCan2025
Reposted
We knew about the potential origin of Parkinson's disease from the gut (known as Braak’s hypothesis). But the kidney?!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease - Nature Neuroscience
Yuan et al. find that the kidney can serve as a site of initiation for the spread of pathological α-synuclein to the brain, contributing to the development of Parkinson’s disease (PD) and providing a ...
www.nature.com
January 23, 2025 at 3:13 PM
We knew about the potential origin of Parkinson's disease from the gut (known as Braak’s hypothesis). But the kidney?!
www.nature.com/articles/s41...
www.nature.com/articles/s41...